Author of

• 12853

  +

  P3.24 - Poster Session 3 - Supportive Care (ID 160)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Supportive Care
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12906

    +

    P3.24-054 - Erlotinib in non-small cell lung cancer: analysis of toxicity and efficacy in clinical practice (ID 3481)

    09:30 - 09:30  |  Author(s): T. Almodovar
    • Abstract

    Background
    Lung cancer is the leading cause of cancer death despite the improvement of therapeutics.Most patients (pts) present with advanced disease when first diagnosed. Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) that is standardtreatment for non-small cell lung cancer (NSCLC) after failure of previous chemotherapy and 1[st] line in EGFR mutated pts. There are few data on toxicity observed in clinical practice described in the literature.

    Methods
    Retrospective study of all consecutive patients with advanced NSCLC treated with erlotinib in our department from October 2005 to November 2012.Primaryendpoint was to evaluate thetoxicity, secondary endpoint was to evaluate time to progression and survival. Data were obtained from clinical files and namely:demographics, histology, performance status (ECOG), stage and toxicity according to common terminology criteria for adverse events (CTCAE) version 4.

    Results
    From the 194pts treated with erlotinib, 111 pts (57%) were male and 83(43%) female, with a median age of 62 years (range 28-92); 37(19%) pts were former smokers, 87(45%) smokers and 70(36%) non-smokers. Histology was adenocarcinoma in 146 (75%) pts, squamous-cell in 25 (13%) and NSCLC-NOS in 23 (12%). Mutation: 21(11%) pts were EGFR mutated. Staging at the diagnosis: III in 71(37%) pts and IV 123(63%) pts. Before erlotinib 93(48%) pts had one line-chemotherapy, 79(41%) two-lines and 3 more than two-lines. Most commons used regimens were platin-based. Skin toxicity was observed in 85 pts (20 pts G2/3 toxicity) and gastro-intestinal toxicity in 21pts, 9 pts with G2/3 toxicity; 4 stop treatment due to toxicity (2 pts due to gastro-intestinal, 2 due to cutaneous). There were no treatment-related deaths or hospitalization. Complete/partial response was observed in 19(9.8%) pts, stable disease in 51 pts. The median TTP and survival after erlotinib treatment were 2.6 months, range (0.2-61) and 5 months range (0.7-160), respectively (CI 95%) with a median follow-up 6 months, (1- 61). Mutated pts had a longer TTP 9,4 month (6.6-12.2) than non-mutated 2,5 months(2,1-2,9),p< 0,001. Pts with cutaneous toxicity had a better TTP 2 months vs 4.2 months (p< 0.001) and survival 3,9months vs 9.4 months (p<0.001).

    Conclusion
    Although in our data there were no death related-treatments, the toxicity observed was highercomparing tothe literature. The efficacy results were similar. Cutaneous toxicity was positively correlated with better outcomes namely TTP and survival.